“Fc-based Scaffold Multifunctional Tumor Immunotherapeutic Biologics (FBDB™) Innovative Technology Platform”

Booth No: M528

Characteristic

HanchorBio’s proprietary FBDB™ innovative technology platform features multifunctional, multi-target biologics that simultaneously activate both innate and adaptive immunity to eliminate tumors, effectively inhibiting a wide range of solid tumors and hematologic cancers.

Through breakthroughs in multifunctional molecular design and optimized process development in protein drug chemistry and manufacturing controls (CMC), HanchorBio addresses unmet needs in cancer treatment and provides affordable therapeutic options for cancer patients.

Currently, over eight biologic drug candidates based on this platform are in various stages of development, with two self-developed biologics already advancing into clinical stages. In Taiwan, it typically takes pharmaceutical companies about 5.5 years to bring a biologic drug to clinical trial phases. In comparison, HanchorBio has achieved this milestone in just under 2.5 years and 3.5 years respectively for its first two drugs.

Notably, the company’s lead candidate, HCB101, received Investigational New Drug (IND) clearance from both the U.S. Food and Drug Administration (FDA) and Taiwan’s Food and Drug Administration (TFDA) in April and July 2023, respectively — a testament to HanchorBio’s rare capability for independent research, development, and innovation as a biopharmaceutical company.